Work

TP015/#1566 A phase 2, two-stage, study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer (EC)

Year: 2022

Type: article

Study design: Study Protocol

Source: International Journal of Gynecological Cancer

DOI: 10.1136/ijgc-2022-igcs.524

Authors: Rebecca Porter, Nabihah Tayob, Madeline Polak, Hannah Sawyer, Jeanette Gardner, Susana Campos, Carolyn Krasner, Elizabeth Lee, Joyce Liu, Elizabeth Stover, Jennifer Veneris, Alexi Wright, Ursula Matulonis, Panagiotis Konstantinopoulos

Institution: Dana-Farber Cancer Institute

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4312139262

FWCI: 0.503

Cites: 1

Cited by: 3

Related to: 10